These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23206324)

  • 1. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.
    Hong J; Novick D; Brugnoli R; Karagianis J; Dossenbach M; Haro JM
    BMC Psychiatry; 2012 Dec; 12():218. PubMed ID: 23206324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
    Haro JM; Novick D; Suarez D; Roca M
    J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.
    Faries DE; Ascher-Svanum H; Nyhuis AW; Kinon BJ
    Curr Med Res Opin; 2008 May; 24(5):1399-405. PubMed ID: 18397549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
    Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
    Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
    J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific.
    Lee CT; Conde BJ; Mazlan M; Visanuyothin T; Wang A; Wong MM; Walker DJ; Roychowdhury SM; Wang H; Tran PV
    J Clin Psychiatry; 2002 Jul; 63(7):569-76. PubMed ID: 12143912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.
    Noordsy DL; Glynn SM; Sugar CA; O'Keefe CD; Marder SR
    J Psychiatr Res; 2017 Dec; 95():299-307. PubMed ID: 28942217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
    Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.
    Kilzieh N; Todd-Stenberg JA; Kennedy A; Wood AE; Tapp AM
    J Clin Psychopharmacol; 2008 Feb; 28(1):74-7. PubMed ID: 18204345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study.
    Novick D; Haro JM; Suarez D; Marques-Teixeira J; Naber D
    Int Clin Psychopharmacol; 2008 Jul; 23(4):203-8. PubMed ID: 18545058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].
    Meder J; Debowska G; Lis J; Araszkiewicz A; Sierosławska K; Kolesaric A; Treuer T
    Psychiatr Pol; 2004; 38(3):469-84. PubMed ID: 15199656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.